☆ 4.6 Article

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

LANCET RESPIRATORY MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, Research & Experimental

The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19

Alexander P. J. Vlaar et al.

Summary: This study reports the pharmacokinetic/pharmacodynamic (PK/PD) analysis of using the monoclonal antibody vilobelimab (IFX-1) to selectively block C5a in patients with severe COVID-19. The results demonstrate that vilobelimab efficiently inhibits C5a and has a favorable safety profile.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

添加到收藏夹

Letter Critical Care Medicine

mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland

Matthias Peter Hilty et al.

INTENSIVE CARE MEDICINE (2022)

添加到收藏夹

Article Hematology

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19

Sistiana Aiello et al.

Summary: The study sheds light on the role of the C5a/C5aR1 axis in endothelial dysfunction and loss of antithrombogenic properties. It demonstrates that C5a mediates the release of vWF and P-selectin, leading to enhanced vWF binding on the endothelium and platelet adhesion and aggregation. These pathogenic mechanisms are also observed in severe COVID-19 patients. Selective C5a/C5aR1 blockade could be a potential therapeutic strategy.

BLOOD ADVANCES (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality

Aditya Shah et al.

ANNALS OF INTERNAL MEDICINE (2022)

添加到收藏夹

Article Immunology

The state of complement in COVID-19

Behdad Afzali et al.

Summary: Hyperactivation of the complement system is implicated in the pathology of COVID-19, with potential therapeutic benefits through complement inhibition. Latest research progress suggests targeting complement components for treatment may be beneficial in mitigating excessive inflammation and thrombosis in severe COVID-19 cases.

NATURE REVIEWS IMMUNOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population

Farhan S. Cyprian et al.

Summary: This study aimed to identify high-risk patients at the time of SARS-COV-2 infection who may develop severe disease associated with low survival using blood parameters, including inflammation and coagulation mediators, vital signs, and pre-existing comorbidities.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Clinical features and prognostic factors in Covid-19: A prospective cohort study

Sanne de Bruin et al.

Summary: The study found that clinical deterioration in patients with severe COVID-19 involves multiple pathways, including chemotaxis and interleukin production, but also endothelial dysfunction, the complement system, and immunothrombosis. Prognostic markers showed considerable overlap between general ward and ICU patients, but we identified distinct differences between groups that should be considered in the development and timing of interventional therapies in COVID-19.

EBIOMEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Manu Shankar-Hari et al.

Summary: This study identified 27 clinical trials and found that the use of IL-6 antagonists was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19 compared to usual care or placebo. Different risk effects were observed between tocilizumab and sarilumab, increasing understanding of the treatment with these drugs.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Complement inhibition in severe COVID-19-Blocking C5a seems to be key

Endry H. T. Lim et al.

ECLINICALMEDICINE (2021)

添加到收藏夹

Review Medicine, General & Internal

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review

W. Joost Wiersinga et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Julien Carvelli et al.

NATURE (2020)

添加到收藏夹

Article Rheumatology

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Djillali Annane et al.

ECLINICALMEDICINE (2020)

添加到收藏夹

Article Immunology

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition

Niels C. Riedemann et al.

CLINICAL IMMUNOLOGY (2017)

添加到收藏夹

Letter Medicine, General & Internal

The Nature of the P Value

Daniel Hu

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Immunology

Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys

Shihui Sun et al.

CLINICAL INFECTIOUS DISEASES (2015)

添加到收藏夹

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.